- Home
- EYE vs OPT Comparison
EYE vs OPT Comparison
Compare EYE & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYE
- OPT
- Stock Information
- Founded
- EYE 1990
- OPT 1984
- Country
- EYE United States
- OPT Australia
- Employees
- EYE N/A
- OPT N/A
- Industry
- EYE Ophthalmic Goods
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EYE Health Care
- OPT Health Care
- Exchange
- EYE Nasdaq
- OPT Nasdaq
- Market Cap
- EYE 870.5M
- OPT 767.9M
- IPO Year
- EYE 2017
- OPT 2020
- Fundamental
- Price
- EYE $11.03
- OPT $3.24
- Analyst Decision
- EYE Buy
- OPT Strong Buy
- Analyst Count
- EYE 3
- OPT 1
- Target Price
- EYE $14.00
- OPT $12.00
- AVG Volume (30 Days)
- EYE 1.5M
- OPT 39.0K
- Earning Date
- EYE 11-06-2024
- OPT 08-30-2024
- Dividend Yield
- EYE N/A
- OPT N/A
- EPS Growth
- EYE N/A
- OPT N/A
- EPS
- EYE N/A
- OPT N/A
- Revenue
- EYE $2,177,092,000.00
- OPT $261,859.00
- Revenue This Year
- EYE N/A
- OPT N/A
- Revenue Next Year
- EYE $2.96
- OPT $46,864.64
- P/E Ratio
- EYE N/A
- OPT N/A
- Revenue Growth
- EYE 20.66
- OPT N/A
- 52 Week Low
- EYE $9.56
- OPT $1.79
- 52 Week High
- EYE $24.11
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- EYE 52.65
- OPT 27.29
- Support Level
- EYE $11.38
- OPT $4.02
- Resistance Level
- EYE $11.93
- OPT $4.18
- Average True Range (ATR)
- EYE 0.62
- OPT 0.22
- MACD
- EYE 0.00
- OPT -0.13
- Stochastic Oscillator
- EYE 39.25
- OPT 6.85
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.